These include poly adenosine diphosphate–(ADP)-ribose polymerase inhibitors (PARPi) for patients with germline BRCA1/2 mutations (which is especially relevant for TNBC), FDA-approved in 2019 for metastatic disease then in 2021 for early disease3–5 as well as the first immunotherapy regimens for TNBC, also approved for metastatic disease beginning in 2019 and for early disease in 20216,7. Here, BRCA1 is linked to metastatic neoplasm.